Skip to main content
OpenTrials
Completed

NCT Number: NCT03624595

Low-dose Dexmedetomidine and Postoperative Delirium After Cardiac Surgery

Delirium is an acutely occurred and fluctuating cerebral dysfunction characterized with inattention, altered consciousness, cognitive decline and/or abnormal perception. It is common in the elderly after cardiac surgery and is associated with worse outcomes. Causes leading to delirium are multifactorial but sleep disturbances remains an important one. In previous studies, sedative-dose dexmedetomidine improves sleep quality in ICU patients with mechanical ventilation; and low-dose dexmedetomidine improves sleep quality in postoperative patients without mechanical ventilation. In recent studies of elderly after noncardiac surgery, night-time infusion of low-dose dexmedetomidine reduces delirium and improves 2-year survival. The investigators hypothesize that, for elderly patients after cardiac surgery, night-time infusion of dexmedetomidine may also improve sleep quality, reduce delirium development and improve 2-year survival.

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beijing University First Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

About this study

Delirium is an acutely occurred and fluctuating cerebral dysfunction characterized with inattention, altered consciousness, cognitive decline and/or abnormal perception. It is common in the elderly after cardiac surgery and is associated with worse outcomes.

The development of delirium is a consequence of multiple factors. For patients undergoing cardiac surgery, surgical stress and/or cardiopulmonary bypass can produce hyper-inflammatory and stress response, both of which are important factors leading to delirium. Meanwhile, patients in ICU after major surgery often develop sleep disturbances, which are also associated with increased risk of delirium.

Dexmedetomidine is a highly selective α2-adrenoceptor agonist with sedative, analgesic and anxiolytic properties. In previous studies of elderly patients admitted to ICU after non-cardiac surgery, continuous infusion of low-dose dexmedetomidine during nighttime improves sleep quality, reduces delirium, and improves 2-year survival.

The investigators hypothesize that, for patients admitted to ICU after cardiac surgery, nighttime infusion of low-dose dexmedetomidine can decrease the incidence of delirium and improve long-term survival. The purpose of this study is to investigate the effect of nighttime infusion of low-dose dexmedetomidine on postoperative sleep quality, delirium, and 2-year survival in elderly patients admitted to ICU after cardiac surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥60 years but <90 years;
  • Scheduled to undergo cardiac surgery with cardiopulmonary bypass under general anesthesia;
  • Expected to stay in the intensive care unit (ICU) for at least 1 night after surgery.

Exclusion criteria

Patients who meet any of the following criteria will be excluded.

  • Refuse to participate in the study;
  • Preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis;
  • Preoperative obstructive sleep apnea (previously diagnosed as obstructive sleep apnea, or the snoring, tiredness, observed apnea, high blood pressure-body mass index, age, neck circumference and gender [STOP-Bang] questionnaires ≥3);
  • Inability to communicate during the preoperative period because of coma, profound dementia or language barrier;
  • Preoperative sick sinus syndrome, severe sinus bradycardia (< 50 beats per minute), or second-degree atrioventricular block or above without pacemaker;
  • Severe hepatic dysfunction (Child-Pugh class C);
  • Severe renal dysfunction (requirement of renal replacement therapy) before surgery;
  • Presence of delirium (diagnosed by the Confusion Assessment Method [CAM]/CAM for the Intensive Care Unit [CAM-ICU]);
  • Current treatment with dexmedetomidine or clonidine.

Treatment and study plan

Dexmedetomidine

Drug

Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.

Other names: Low-dose dexmedetomidine infusion

Placebo

Drug

Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.

Other names: Normal saline infusion

Primary outcomes

  1. Incidence of delirium within the first 5 days after surgery

    Time frame: During the first 5 days after surgery

    Delirium is assessed twice daily (8:00-10:00 am, 18:00-20:00 pm) with the Confusion Assessment Method (CAM, for patients without mechanical ventilation) or CAM for the intensive care unit (CAM-ICU, for patients with mechanical ventilation) during postoperative days 1-5.

Secondary outcomes

  1. Duration of mechanical ventilation after surgery

    Time frame: Up to 30 days after surgery

    Duration of mechanical ventilation after surgery

  2. Length of stay in ICU after surgery

    Time frame: Up to 30 days after surgery

    Length of stay in ICU after surgery

  3. Length of stay in hospital after surgery

    Time frame: Up to 30 days after surgery

    Length of stay in hospital after surgery

  4. Incidence of Major Adverse Cardiovascular Events (MACEs) within 30 days after surgery

    Time frame: Up to 30 days after surgery

    Postoperative Major Adverse Cardiac Events (MACEs) include in-hospital death, myocardial infarction, second surgery, non-fetal cardiac arrest/ventricular fibrillation, and stroke. The occurrence of major postoperative events is followed up twice daily during postoperative days 1-5, then once a week until 30 days after surgery.

  5. Incidence of other complications

    Time frame: Up to 30 days after surgery

    Incidence of other complications (including hospital re-admission) within 30 days after surgery.

  6. All-cause 30-day mortality

    Time frame: At 30 days after surgery

    All-cause mortality within 30 days after surgery

  7. Subjective sleep quality at 30 days after surgery

    Time frame: At 30 days after surgery

    Subjective sleep quality at 30 days after surgery is assessed with Pittsburgh sleep quality index (PSQI)

Other outcomes

  1. Alterations of sleep architecture (a subset of patients)

    Time frame: During the night of surgery

    Sleep architecture is monitored with polysomnograph from 21:00 pm in the night of surgery to 06:00 am on the first day after surgery in part of enrolled patients (selected according to randomization block).

  2. The Numeric Rating Scale (NRS) pain score within 5 days after surgery.

    Time frame: At 2, 6, 24, 48, 72, 96, and 120 hours (i.e., the 5th day) after surgery.

    The Numeric Rating Scale (NRS) pain score is assessed with the NRS (an 11-point scale where 0=no pain and 10=the worst pain).

  3. Subjective sleep quality within 5 days after surgery

    Time frame: During the first 5 days after surgery

    Subjective sleep quality is assessed with NRS (an 11-point scale where 0=the best sleep and 10=the worst sleep) once daily (8:00-10:00 am) during postoperative days 1-5.

  4. Daily prevalence of delirium during postoperative days 1-5

    Time frame: During the first 5 days after surgery

    Daily prevalence of delirium during postoperative days 1-5

  5. Major Adverse Cardiac and Cerebrovascular Events (MACCEs)-free survival after surgery

    Time frame: Up to 4 years after surgery of the last enrolled patient

    Major Adverse Cardiac and Cerebrovascular Events (MACCEs) include cardiac death, myocardial infarction, revascularization, and stroke.

  6. Overall survival after surgery

    Time frame: Up to 4 years after surgery of the last enrolled patient

    Overall survival after surgery

  7. Cognitive function in 1- and 2-year survivors

    Time frame: At the end of the 1st and 2nd years after surgery

    Cognitive function in 1- and 2-year survivors is assessed with the modified Telephone Interview for Cognitive Status (TICS-m, score ranges from 0 to 40, with higher score indicating better function).

  8. Quality of life in 1- and 2- year survivors

    Time frame: At the end of the 1st and 2nd years after surgery

    Quality of life in 1- and 2-year survivors is assessed with the 36-Item Short Form Health Survey (SF-36). The SF-36 evaluates 8 different domains of quality of life, i.e., physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The score of each domain ranges from 0 to 100, with high score indicating better function.

Sponsors and collaborators

Lead sponsor

Dong-Xin Wang

Other

Collaborators

  • Fu Wai Hospital, Beijing, China

Registry information

Official study title

Effect of Low-dose Dexmedetomidine on Postoperative Delirium in Patients After Cardiac Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial

Important dates

Study start
2019
Primary completion
2021
Study completion
2025
First posted
Aug 10, 2018
Registry last updated
Apr 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.